Long-acting protein drugs for the treatment of ocular diseases
Retinal vascular disease treatments involve frequent pharmacological intraocular administrations. Here the authors present a method to increase the half-life of injected drugs by fusing these to a hyaluronan-binding peptide, which might lead to less frequent retinal disease treatments.
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2017-03-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/ncomms14837 |
| id |
doaj-f0adf43d440f4267b734d5d4506d7186 |
|---|---|
| record_format |
Article |
| spelling |
doaj-f0adf43d440f4267b734d5d4506d71862021-05-11T07:35:20ZengNature Publishing GroupNature Communications2041-17232017-03-018111010.1038/ncomms14837Long-acting protein drugs for the treatment of ocular diseasesJoy G. Ghosh0Andrew A. Nguyen1Chad E. Bigelow2Stephen Poor3Yubin Qiu4Nalini Rangaswamy5Richard Ornberg6Brittany Jackson7Howard Mak8Tucker Ezell9Vania Kenanova10Elisa de la Cruz11Ana Carrion12Bijan Etemad-Gilbertson13Roxana Garcia Caro14Kan Zhu15Vinney George16Jirong Bai17Radhika Sharma-Nahar18Siyuan Shen19Yiqin Wang20Kulandayan K. Subramanian21Elizabeth Fassbender22Michael Maker23Shawn Hanks24Joanna Vrouvlianis25Barrett Leehy26Debby Long27Melissa Prentiss28Viral Kansara29Bruce Jaffee30Thaddeus P. Dryja31Michael Roguska32Novartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchNovartis Institutes for BioMedical ResearchRetinal vascular disease treatments involve frequent pharmacological intraocular administrations. Here the authors present a method to increase the half-life of injected drugs by fusing these to a hyaluronan-binding peptide, which might lead to less frequent retinal disease treatments.https://doi.org/10.1038/ncomms14837 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Joy G. Ghosh Andrew A. Nguyen Chad E. Bigelow Stephen Poor Yubin Qiu Nalini Rangaswamy Richard Ornberg Brittany Jackson Howard Mak Tucker Ezell Vania Kenanova Elisa de la Cruz Ana Carrion Bijan Etemad-Gilbertson Roxana Garcia Caro Kan Zhu Vinney George Jirong Bai Radhika Sharma-Nahar Siyuan Shen Yiqin Wang Kulandayan K. Subramanian Elizabeth Fassbender Michael Maker Shawn Hanks Joanna Vrouvlianis Barrett Leehy Debby Long Melissa Prentiss Viral Kansara Bruce Jaffee Thaddeus P. Dryja Michael Roguska |
| spellingShingle |
Joy G. Ghosh Andrew A. Nguyen Chad E. Bigelow Stephen Poor Yubin Qiu Nalini Rangaswamy Richard Ornberg Brittany Jackson Howard Mak Tucker Ezell Vania Kenanova Elisa de la Cruz Ana Carrion Bijan Etemad-Gilbertson Roxana Garcia Caro Kan Zhu Vinney George Jirong Bai Radhika Sharma-Nahar Siyuan Shen Yiqin Wang Kulandayan K. Subramanian Elizabeth Fassbender Michael Maker Shawn Hanks Joanna Vrouvlianis Barrett Leehy Debby Long Melissa Prentiss Viral Kansara Bruce Jaffee Thaddeus P. Dryja Michael Roguska Long-acting protein drugs for the treatment of ocular diseases Nature Communications |
| author_facet |
Joy G. Ghosh Andrew A. Nguyen Chad E. Bigelow Stephen Poor Yubin Qiu Nalini Rangaswamy Richard Ornberg Brittany Jackson Howard Mak Tucker Ezell Vania Kenanova Elisa de la Cruz Ana Carrion Bijan Etemad-Gilbertson Roxana Garcia Caro Kan Zhu Vinney George Jirong Bai Radhika Sharma-Nahar Siyuan Shen Yiqin Wang Kulandayan K. Subramanian Elizabeth Fassbender Michael Maker Shawn Hanks Joanna Vrouvlianis Barrett Leehy Debby Long Melissa Prentiss Viral Kansara Bruce Jaffee Thaddeus P. Dryja Michael Roguska |
| author_sort |
Joy G. Ghosh |
| title |
Long-acting protein drugs for the treatment of ocular diseases |
| title_short |
Long-acting protein drugs for the treatment of ocular diseases |
| title_full |
Long-acting protein drugs for the treatment of ocular diseases |
| title_fullStr |
Long-acting protein drugs for the treatment of ocular diseases |
| title_full_unstemmed |
Long-acting protein drugs for the treatment of ocular diseases |
| title_sort |
long-acting protein drugs for the treatment of ocular diseases |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2017-03-01 |
| description |
Retinal vascular disease treatments involve frequent pharmacological intraocular administrations. Here the authors present a method to increase the half-life of injected drugs by fusing these to a hyaluronan-binding peptide, which might lead to less frequent retinal disease treatments. |
| url |
https://doi.org/10.1038/ncomms14837 |
| work_keys_str_mv |
AT joygghosh longactingproteindrugsforthetreatmentofoculardiseases AT andrewanguyen longactingproteindrugsforthetreatmentofoculardiseases AT chadebigelow longactingproteindrugsforthetreatmentofoculardiseases AT stephenpoor longactingproteindrugsforthetreatmentofoculardiseases AT yubinqiu longactingproteindrugsforthetreatmentofoculardiseases AT nalinirangaswamy longactingproteindrugsforthetreatmentofoculardiseases AT richardornberg longactingproteindrugsforthetreatmentofoculardiseases AT brittanyjackson longactingproteindrugsforthetreatmentofoculardiseases AT howardmak longactingproteindrugsforthetreatmentofoculardiseases AT tuckerezell longactingproteindrugsforthetreatmentofoculardiseases AT vaniakenanova longactingproteindrugsforthetreatmentofoculardiseases AT elisadelacruz longactingproteindrugsforthetreatmentofoculardiseases AT anacarrion longactingproteindrugsforthetreatmentofoculardiseases AT bijanetemadgilbertson longactingproteindrugsforthetreatmentofoculardiseases AT roxanagarciacaro longactingproteindrugsforthetreatmentofoculardiseases AT kanzhu longactingproteindrugsforthetreatmentofoculardiseases AT vinneygeorge longactingproteindrugsforthetreatmentofoculardiseases AT jirongbai longactingproteindrugsforthetreatmentofoculardiseases AT radhikasharmanahar longactingproteindrugsforthetreatmentofoculardiseases AT siyuanshen longactingproteindrugsforthetreatmentofoculardiseases AT yiqinwang longactingproteindrugsforthetreatmentofoculardiseases AT kulandayanksubramanian longactingproteindrugsforthetreatmentofoculardiseases AT elizabethfassbender longactingproteindrugsforthetreatmentofoculardiseases AT michaelmaker longactingproteindrugsforthetreatmentofoculardiseases AT shawnhanks longactingproteindrugsforthetreatmentofoculardiseases AT joannavrouvlianis longactingproteindrugsforthetreatmentofoculardiseases AT barrettleehy longactingproteindrugsforthetreatmentofoculardiseases AT debbylong longactingproteindrugsforthetreatmentofoculardiseases AT melissaprentiss longactingproteindrugsforthetreatmentofoculardiseases AT viralkansara longactingproteindrugsforthetreatmentofoculardiseases AT brucejaffee longactingproteindrugsforthetreatmentofoculardiseases AT thaddeuspdryja longactingproteindrugsforthetreatmentofoculardiseases AT michaelroguska longactingproteindrugsforthetreatmentofoculardiseases |
| _version_ |
1721451956271054848 |